Get startedLog in
    Picture of Sino Biopharmaceutical logo

    1177 — Sino Biopharmaceutical News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareAdventurousLarge CapNeutral
    All News

    Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate

    Picture of Sino Biopharmaceutical logoSino Biopharmaceutical
    31/08/2026 11:16
    BRIEF-Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate
    Aug 31 (Reuters) - Cipla Ltd CIPL.NS:
    • CO AND SBP GROUP SIGN EXCLUSIVE LICENSING AGREEMENT FOR HER2 BISPECIFIC ADC TQB2102
    • RECEIVES EXCLUSIVE RIGHTS TO DEVELOP TQB2102 IN INDIA, SOUTH AFRICA AND 5 MARKETS
    Source text: ID:nBSE68xVd
    Further company coverage: CIPL.NS

     ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Sino Biopharmaceutical

    See all news